Is Neumora Therapeutics, Inc. (NMRA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.4% / 30% | 59.9% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.4% / 33% | 59.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.6% / 33% | 97.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.4% / 33% | 59.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.6% / 33% | 97.0% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -104.3% | |
| Return on Assets (ROA) | -56.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$183M |
| Free Cash Flow | -$183M |
| Total Debt | $2M |
| Debt-to-Equity | 15.2 |
| Current Ratio | 6.9 |
| Total Assets | $317M |
Price & Trading
| Last Close | $2.49 |
| 50-Day MA | $2.71 |
| 200-Day MA | $2.04 |
| Avg Volume | 1.6M |
| Beta | 2.5 |
|
52-Week Range
$0.61
| |
About Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease. In addition, the company's preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Neumora Therapeutics, Inc. (NMRA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Neumora Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Neumora Therapeutics, Inc.'s debt ratio?
Neumora Therapeutics, Inc.'s debt ratio is 0.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.6%.
What are Neumora Therapeutics, Inc.'s key financial metrics?
Neumora Therapeutics, Inc. has a market capitalization of $396M. Return on equity stands at -104.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.